摘要
目的:观察构建含人的肿瘤侵袭和转移的特异性抗原CD44v5编码基因的真核表达的重组载体,为进一步研究CD44v5修饰的DC融合瘤苗的免疫治疗作用及机制提供实验依据及理论基础。方法:以pcDNA3.1作为真核表达载体,选择CD44v5编码基因进行RT-PCR扩增,构建重组表达质粒,进行酶切鉴定和测序分析。结果:经酶切鉴定和测序分析表明,插入的目的基因片段为CD44v5的编码基因,由129bp组成,与GeneBank中登录的cDNA相比较,同源性高达100%,且方向正确。结论:成功构建了pcDNA3.1-CD44v5真核表达的重组载体,为下一步构建和研究以CD44v5修饰的DC融合瘤苗抗肿瘤作用及其机制奠定了基础。
Objective:To construct the eukaryon gene expression vector for CD44v5.Methods:CD44v5 gene was amplified by RTPCR and cloned into plasmid pcDNA3.1 to form the recombinant plasmid pcDNA3.1-CD44v5,which was then indentified by the technol-ogy of restriction digest and nucleotides sequencing.Results:The restriction digest and sequence analysis demonstrated that this 129bp of CD44v5 gene was the same as that published on GeneBank,and it was inserted into the vector accurately.Conclusion:A new plasmid of pBud-CD44v5 has been successfully established.This study is the basic foundation for our next experiment on studying the anti-tumor effect and mechanism of fusion hybrid of DCs expression CD44v5.
出处
《现代医药卫生》
2010年第12期1766-1767,共2页
Journal of Modern Medicine & Health